AC Immune (ACIU) Competitors $3.19 -0.36 (-10.14%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends ACIU vs. BCAX, ZYME, CALT, APLT, ARDX, BCYC, AVBP, COGT, MESO, and IMTXShould you be buying AC Immune stock or one of its competitors? The main competitors of AC Immune include Bicara Therapeutics (BCAX), Zymeworks (ZYME), Calliditas Therapeutics AB (publ) (CALT), Applied Therapeutics (APLT), Ardelyx (ARDX), Bicycle Therapeutics (BCYC), ArriVent BioPharma (AVBP), Cogent Biosciences (COGT), Mesoblast (MESO), and Immatics (IMTX). These companies are all part of the "pharmaceutical products" industry. AC Immune vs. Bicara Therapeutics Zymeworks Calliditas Therapeutics AB (publ) Applied Therapeutics Ardelyx Bicycle Therapeutics ArriVent BioPharma Cogent Biosciences Mesoblast Immatics AC Immune (NASDAQ:ACIU) and Bicara Therapeutics (NASDAQ:BCAX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends. Do analysts prefer ACIU or BCAX? AC Immune currently has a consensus target price of $12.00, suggesting a potential upside of 276.18%. Bicara Therapeutics has a consensus target price of $43.33, suggesting a potential upside of 114.84%. Given AC Immune's higher probable upside, equities research analysts clearly believe AC Immune is more favorable than Bicara Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AC Immune 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Bicara Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Does the MarketBeat Community favor ACIU or BCAX? AC Immune received 252 more outperform votes than Bicara Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Bicara Therapeutics an outperform vote while only 62.47% of users gave AC Immune an outperform vote. CompanyUnderperformOutperformAC ImmuneOutperform Votes25862.47% Underperform Votes15537.53% Bicara TherapeuticsOutperform Votes6100.00% Underperform VotesNo Votes Is ACIU or BCAX more profitable? Bicara Therapeutics' return on equity of 0.00% beat AC Immune's return on equity.Company Net Margins Return on Equity Return on Assets AC ImmuneN/A -28.26% -18.98% Bicara Therapeutics N/A N/A N/A Which has preferable earnings & valuation, ACIU or BCAX? Bicara Therapeutics has lower revenue, but higher earnings than AC Immune. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAC Immune$16.48M19.15-$60.41M-$0.46-6.93Bicara TherapeuticsN/AN/AN/AN/AN/A Do institutionals & insiders believe in ACIU or BCAX? 51.4% of AC Immune shares are owned by institutional investors. 4.6% of AC Immune shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the media favor ACIU or BCAX? In the previous week, AC Immune had 1 more articles in the media than Bicara Therapeutics. MarketBeat recorded 11 mentions for AC Immune and 10 mentions for Bicara Therapeutics. AC Immune's average media sentiment score of 0.93 beat Bicara Therapeutics' score of 0.29 indicating that AC Immune is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AC Immune 3 Very Positive mention(s) 5 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bicara Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryAC Immune beats Bicara Therapeutics on 7 of the 13 factors compared between the two stocks. Ad Colonial Metals“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as we wait for Trump's agenda to kick in…>> YES! Send Me My FREE Gold Guide! Get AC Immune News Delivered to You Automatically Sign up to receive the latest news and ratings for ACIU and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACIU vs. The Competition Export to ExcelMetricAC ImmunePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$315.62M$6.53B$5.15B$8.74BDividend YieldN/A8.16%5.18%4.08%P/E Ratio-6.934.7865.5913.48Price / Sales19.15377.381,278.7587.67Price / CashN/A51.2039.7035.24Price / Book2.109.686.475.93Net Income-$60.41M$154.43M$119.73M$225.73M7 Day Performance-0.31%-9.46%-5.13%-1.34%1 Month Performance-0.62%-7.27%-2.71%1.15%1 Year Performance3.24%28.13%31.08%24.02% AC Immune Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACIUAC Immune2.3541 of 5 stars$3.19-10.1%$12.00+276.2%+10.0%$315.62M$16.48M-6.93140Analyst ForecastShort Interest ↑News CoverageBCAXBicara Therapeutics3.5886 of 5 stars$24.11+1.2%N/AN/A$1.25BN/A0.0032Earnings ReportAnalyst RevisionNews CoverageZYMEZymeworks2.1027 of 5 stars$17.33+4.2%N/A+97.8%$1.19B$76.01M-11.55290CALTCalliditas Therapeutics AB (publ)0.1943 of 5 stars$40.00flatN/AN/A$1.19B$1.60B-21.62180News CoverageAPLTApplied Therapeutics4.4519 of 5 stars$10.24+1.5%N/A+338.9%$1.18B$9.99M-6.3630Short Interest ↓News CoverageARDXArdelyx4.0429 of 5 stars$4.90-3.5%N/A+23.3%$1.16B$124.46M-16.32267Short Interest ↑Analyst RevisionGap UpHigh Trading VolumeBCYCBicycle Therapeutics2.8616 of 5 stars$24.32-2.6%N/A+55.8%$1.16B$26.98M-7.39240Insider SellingShort Interest ↑AVBPArriVent BioPharma1.0349 of 5 stars$34.33+0.4%N/AN/A$1.15BN/A0.0040Analyst ForecastNews CoverageCOGTCogent Biosciences2.7391 of 5 stars$10.40+1.9%N/A+20.6%$1.14BN/A-4.1980Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageMESOMesoblast1.5914 of 5 stars$9.74+6.0%N/A+298.4%$1.11B$5.90M0.0080News CoverageGap DownIMTXImmatics2.3332 of 5 stars$9.04-2.3%N/A-3.9%$1.08B$58.44M-10.16260Short Interest ↓ Related Companies and Tools Related Companies Bicara Therapeutics Competitors Zymeworks Competitors Calliditas Therapeutics AB (publ) Competitors Applied Therapeutics Competitors Ardelyx Competitors Bicycle Therapeutics Competitors ArriVent BioPharma Competitors Cogent Biosciences Competitors Mesoblast Competitors Immatics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ACIU) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AC Immune SA Please log in to your account or sign up in order to add this asset to your watchlist. Share AC Immune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
